上市：
| 产品编号 | 产品名称 | 产品简述 | 应用领域 | 参考文献 | 客户反馈 |
| SB431542 | SB431542是激活素受体样激酶ALK-4，ALK-5和ALK-7受体抑制剂。 |
[1] Davies MR, et al. PLoS One, 2016, 11(5), e0155486. [2] Madhu V, et al. Stem Cells Int, 2016, 1035374. [3] Tanaka H, et al. Oncol Rep, 2010, 24(6), 1637-1643. [1] Davies MR, et al. PLoS One, 2016, 11(5), e0155486. |
   |
||
| LDN193189 (DM 3189) | LDN193189 (DM 3189)是BMP信号通路抑制剂，用于治疗非小细胞肺癌。 |
Ali JL, et al. Int J Cancer, 2015, 136(5), E455-469. Whissell G, et al. Nat Cell Biol, 2014, 16(7), 695-707. Hong CC, et al. Cytokine Growth Factor Rev, 2009, 20(5-6), 409-418. Steinbicker AU, et al. Blood, 2011, 117(18), 4915-4923. |
|
||
| Galunisertib (LY2157299) | Galunisertib (LY2157299)是一种有效的TGF-beta抑制剂，用于治疗前列腺癌、转移性乳腺癌和神经胶质瘤。 |
骨髓增生异常综合征 |
Bueno L, et al. Eur J Cancer. 2008 Jan;44(1):142-50. Maier A, et al. Cell Oncol (Dordr), 2015, 38(2), 131-144. Herbertz S, et al. Drug Des Devel Ther, 2015, 9, 4479-4799. Bhola NE, et al. J Clin Invest, 2013, 123(3), 1348-1358. |
|
|
| Staurosporine | Staurosporine 是用于治疗急性骨髓性白血病的强效细胞透性蛋白激酶C抑制剂。 |
白血病 |
Ikegami Y, et al. Arzneimittelforschung, 1995, 45(11), 1225-1230. Ikegami Y, et al. Arzneimittelforschung, 1996, 46(2), 201-204. Kumar S, et al. J Cancer Res Ther, 2015, 11(4), 904-910. Fabbro D, et al. Pharmacol Ther, 1999, 82(2-3), 293-301. |
|
|
| LY2109761 | LY2109761是选择性TGF-beta受体I/II抑制剂，用于治疗胶质母细胞瘤，胰腺癌和肝细胞癌。 |
Melisi D, et al. Mol Cancer Ther, 2008, 7(4), 829-840. Zhang M, et al. Cancer Res, 2011, 71(23), 7155-7167. Gao Y, et al. Int J Clin Exp Pathol, 2015, 8(5), 4923-4932. Connolly EC, et al. Cancer Res, 2011, 71(6), 2339-2349. |
|
||
| Sotrastaurin | Sotrastaurin是PKC抑制剂用于治疗黑色素瘤。 |
淋巴瘤,黑色素瘤 |
Naylor TL, et al. Cancer Res. 2011 Apr 1;71(7):2643-53. Weckbecker G, et al. Transpl Int, 2010, 23(5), 543-552. Fang YH, et al. J Surg Res. 2011 Nov;171(1):e133-7. Wagner J, et al. J Med Chem, 2011, 54(17), 6028-6039. |
|
|
| GW788388 | GW788388是选择性TGF-beta受体I抑制剂。 |
Gellibert F, et al. J Med Chem, 2006, 49(7), 2210-2221. [2]Petersen M, et al. Kidney Int. 2008 Mar;73(6):705-15. de Oliveira FL, et al. PLoS Negl Trop Dis, 2012, 6(6), e1696. Connolly EC, et al. Cancer Res, 2011, 71(6), 2339-2349. |
|
||
| Pirfenidone | Pirfenidone能够抑制TGF-β诱导的胶原产生，激动ECM聚集与成纤维细胞的增殖，用于特发性纤维化的治疗。 |
特发性间质性肺炎 |
Kozono S, et al. Cancer Res, 2013, 73(7), 2345-2356. Mediavilla-Varela M, et al. BMC Cancer, 2016, 16, 176. Oku H, et al. Eur J Pharmacol, 2002, 446(1-3), 167-176. Kehrer JP, et al. Toxicol Lett, 1997, 90(2-3), 125-132. |
|
|
| SB525334 | SB525334是选择性的TGF-beta受体I抑制剂。 |
Grygielko ET, et al. J Pharmacol Exp Ther, 2005, 313(3), 943-951. Laping NJ, et al. Clin Cancer Res, 2007, 13(10), 3087-3099. Thomas M, et al. Am J Pathol, 2009, 174(2), 380-389. Higashiyama H, et al. Exp Mol Pathol, 2007, 83(1), 39-46. |
|
||
| Enzastaurin (LY317615) | Enzastaurin (LY317615)是ATP竞争性PKC-beta抑制剂，主要用于治疗弥漫性大B细胞淋巴瘤。 |
淋巴瘤 |
Graff JR, et al. Cancer Res, 2005, 65(16), 7462-7469. Podar K, et al. Blood, 2007, 109(4), 1669-1677. Moreau AS, et al. Blood, 2007, 109(11), 4964-4972. Lee KW, et al. Cancer Res, 2008, 68(6), 1916-1926. |
|
